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Abstract 
Case report on second case of t(2;21)(q11.2;q22.3) 
in a child with T-cell acute lymphoblastic leukemia. 
Clinics 
Age and sex: 10 years old female patient. 
Previous history: no preleukemia, no pertinent past 
medical history, no previous malignancy, no inborn 
condition of note  
Organomegaly: no hepatomegaly, no 
splenomegaly, no enlarged lymph nodes, no central 
nervous system involvement  
Blood 
WBC: 29.8X 109/l 
HB: 13.4g/dl 
Platelets: 184X 109/l 
Blasts: 0% none seen in peripheral blood.% 
Bone marrow: 70%. The bone marrow shows 
partial involvement of the marrow by blasts with 
abnormal T-cell phenotype similar to the patient's 
mediastinal mass. The blasts represent 72% of cells 
by flow cytometry. Reduced trilineage 
hematopoiesis is present in the background. No 
dysplasia is identified. Megakaryocytes are present 
in normal numbers and show normal morphology. 
Monocytes are not increased. Plasma cells are not 
increased. No iron is identified on Prussian blue 
stain. Differential: Blasts: 70%; Promyelocytes: 4%; 
Myelocytes: 2%; Metamyelocytes: 2%; Neutrophils: 




Cytology L1 ALL 
Immunophenotype Flow cytometric analysis of the 
mediastinal mass shows mostly a T-lineage 
immature cell population (99% of analyzed events) 
expressing: cytoplasmic CD3, CD5, CD7, small 
subset CD11c, CD38, CD45, CD71 and TdT. 
Significantly negative for CD2, surface CD3, CD4, 
CD8, CD10, CD19, CD20, CD13/CD33 and CD34. 
Based on light scatter characteristics the cells are 
enlarged to medium in size and have no increase in 
side scatter. 
Rearranged Ig Tcr Unknown. 
Diagnosis T-cell lymphoblastic acute leukemia. 
Survival 
Date of diagnosis 04/2015 
Treatment 
Chemotherapy per children oncology group (cog) 
protocol aall1231: induction with vincristine, 
daunorubicin, prednisone, peg-asparaginase; 
intrathecal cytarabine/methotrexate.  
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Interphase FISH showing the splitting of one of the RUNX1 signals due to the t(2;21). ETV6 (12p13) is labeled in SpectrumGreen 
and RUNX1 (21q22) in SpectrumOrange. Arrows point to the split RUNX1. 
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Flow cytometric remission after four weeks. 
Consolidation therapy with cyclophosphamide, 
cytarabine, vincristine, peg-asparaginase; intrathecal 
methotrexate. More therapy to follow. 
Complete remission :  Yes (still on therapy) 
Treatment related death : no   
Relapse : no   
Status Alive 
Last follow up 08/2015 
Survival 3months 
Karyotype 
Culture time: 24 and 48 hours unstimulated 
Banding : GTW t 
Results :46,XX,t(2;21)(q11.2;q22.3),ins(3;?)(q21;?
), del(5)(q15q31),del(6)(q13q21) [cp21] 
Karyotype at Relapse: N/A 
Other Molecular Studies 
Technics: FISH ETV6-RUNX1 (12;21) dual-color 
ES translocation probe. Abbott Molecular, Des 
Planes, IL, USA. 
Results: nuc ish(ETV6x2,RUNX1x3)[98/100]. 
 
Comments 
This is the second case of T-ALL with 
t(2;21)(q11.2;q22.3) and involvement of RUNX1. 
The first case, which was reported in 2008, affected 
a 6-year-old boy (Chinen et al. 2008). In the previous 
report, the authors demonstrated that the t(2;21) 
resulted in a fusion between the AFF3 (aka., LAF4) 
and the RUNX1 (aka., AML1) genes located at 
2q11.2 and 21q22.3, respectively. In the present 
case, we used FISH to demonstrate the involvement 
of RUNX1 in the t(2;21). It is, therefore, reasonable 
to assume that the t(2;21) observed here leads to an 
AFF3-RUNX1 fusion as well. AFF3 belongs to a 
family of putative transcription factors also 
comprising AFF1 (4q21), AFF2 (Xq28), and AFF4 
(5q31). In both previous and present cases, the 
t(2;21) is present together with other chromosome 
abnormalities.  
Both patients responded well to the therapeutic 
approach. According to Chinen and coauthors, their 
patient was treated on the Tokyo Children's Cancer 
Study Group (TCCSG) L04-16 extremely high-risk 
(HEX) protocol, including stem cell transplantation. 
He achieved complete remission after the induction 
phase. After the early consolidation phase and two 
courses of the consolidation phase, he received 
allogeneic bone marrow transplantation from an 
unrelated HLA-matched donor 4 months after 
diagnosis. At the time of the case report in 2008, he 
was in complete remission for 17 months. Our 
patient also responded favorably to the therapeutic 
protocol (induction with vincristine, daunorubicin, 
prednisone, peg-asparaginase; intrathecal 
cytarabine/methotrexate; flow cytometric remission 
after four weeks; consolidation therapy with 
cyclophosphamide, cytarabine, vincristine, peg-
asparaginase; intrathecal methotrexate). She is in 
complete remission for 5 months.  
The present case report provides further support that 
the t(2;21) is a rare but recurrent finding in pediatric 
T-ALL.  
This translocation seems to occur together with other 
chromosome abnormalities.  
Patients have responded favorably to the therapy and 
have achieved complete remission. 
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